A nanoparticle carrier system that could eliminate the need for bone marrow transplants, which are both expensive and difficult for patients to undergo. The University of Delaware's Emily Day, an assistant professor of biomedical engineering, is developing a platform that could treat stem cells directly without the need to remove them from the body.
A discovery by Florida State University College of Medicine researchers is expected to open the door for new and more potent treatment options for many of the more than 36 million people worldwide infected with the HIV virus and for others chronically ill with hepatitis B.
Providing multidisciplinary team consults for HIV patients while they are hospitalized to help address social and medical barriers reduces future infection rates and boosts participation in follow-up care, results from a study on how to reengage patients show.
A new study revealed that one dose of the HPV vaccine may prevent infection from the potential cancer-causing virus, according to research published in JAMA Network Open from The University of Texas Health Science Center at Houston (UTHealth).
New direct-acting antiviral (DAA) medications are highly effective in curing patients with hepatitis C virus (HCV). But these drugs carry a risk of interactions with antiretroviral therapy (ART) used to control HIV. An update on management of drug interactions in patients coinfected with HIV/HCV is presented in The Journal of the Association of Nurses in AIDS Care (JANAC). The official journal of the Association of Nurses in AIDS Care, JANAC is published in the Lippincott portfolio by Wolters Kluwer.
Pregnant women living with HIV don’t always receive antiretroviral medications recommended for use in pregnancy, according to a recent study published in Jama Network Open this week. Ann & Robert H. Lurie Children's Hospital of Chicago’s researchers collaborated in the multi-site Surveillance Monitoring for ART Toxicities (SMARTT) study of the Pediatric HIV/AIDS Cohort Study (PHACS) network.
The spending bill passed today is a welcome step forward. Allocations in the bill will strengthen public health and research efforts during the year ahead and will provide critical support for important goals. At the same time, the legislation in its final form also brings inadequate responses to current and urgent challenges with the potential for long-term and costly consequences.
A drug purified and developed from the sap of a tree in the Amazon rainforest is now being studied for the treatment of chronic idiopathic diarrhea in non-HIV patients at The University of Texas Health Science Center at Houston (UTHealth) as part of a two-year pilot study.
Nearly three-fourths of young adults experiencing homelessness who are raped do not seek post-sexual assault medical care, missing an opportunity to greatly reduce their risk of contracting HIV, according to a survey led by The University of Texas Health Science Center at Houston (UTHealth).
H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act passed by the House of Representatives today introduces critically needed and significant steps to reduce costs and improve access to life-saving therapies for conditions including HIV and hepatitis C. Importantly, the legislation also brings essential resources to combat antibiotic resistance, find and develop new infection fighting drugs and bring them to market. The balanced approach of this legislation will serve patients and public health.
This World AIDS Day marks a promising and unprecedented point in a quest begun nearly four decades ago to end the global public health threat of HIV through science and solidarity. Increasingly, effective and essential technologies, medicines and measures to effectively treat the virus and prevent transmissions are finding their way to where they are needed most and are demonstrating that we have what is needed to end this pandemic. For the first time, the United States has developed a plan aiming to end the American epidemic. And in keeping with hard-earned knowledge as well as with the theme of this World AIDS Day, communities are at the center of ambitious responses. Still, this World AIDS Day finds progress stalled by policies and politics that threaten the momentum we have gathered.
Some primates can carry SIV, a virus resembling HIV, lifelong and yet not develop AIDS. They are able to repair SIV damage to intestinal mucous tissues and avoid escape of gut bacteria and other events leading to immune system exhaustion. The findings offer clues for new HIV treatments
Penn Nursing has received a $100,000 grant from the Robert I. Jacobs Fund of the Philadelphia Foundation for HIV research. The grant supports an investigation, “Youth-driven Perspectives in HIV Biomedical Prevention and Cure Research,” led by José A. Bauermeister, PhD, MPH, Presidential Professor of Nursing.
A UC Davis study found that Lactobacillus plantarum bacteria rapidly repaired damaged gut lining (known as leaky gut) in monkeys infected with chronic simian immunodeficiency virus (SIV), an HIV-like virus. It linked chronically inflamed leaky gut to the loss of PPARα signaling and damage to mitochondria.
Rates of new anal cancer diagnoses and deaths related to human papillomavirus (HPV), the most common sexually transmitted infection, have increased dramatically over the last 15 years, according to researchers at The University of Texas Health Science Center at Houston (UTHealth). The results of their study will be published in the November issue of the Journal of the National Cancer Institute.
The success of antiretroviral therapies has extended the lives of people living with HIV, long enough for other chronic health conditions to emerge, including a recently documented uptick in sudden death.
The University at Albany is now the home of an applied modeling center designed to aid the Centers for Disease Control and Prevention (CDC) and state and local public health organizations in developing, implementing and altering public health initiatives.
In support of World Pneumonia Day, Nov. 12, the Forum of International Respiratory Societies (FIRS), of which the American Thoracic Society is a member, calls for an end to preventable pneumonia deaths, ensuring equitable access to interventions for prevention and control of pneumonia.
Wistar scientists applied synthetic DNA-based technology to drive in vivo production of broadly neutralizing anti-HIV antibodies in small and large-animal models, providing proof of concept for a simple and effective next generation approach to HIV prevention and therapy. These results were published online in the Journal of Clinical Investigation.
To end the HIV epidemic in the US, the use of behavioral and social science research—combined with biomedical strategies—is essential, according to a series of new papers in JAIDS. The 15 article supplement was co-edited by two faculty members in the Perelman School of Medicine at the University of Pennsylvania.
An innovative study from the University of Pennsylvania School of Nursing (Penn Nursing) used a youth-driven mystery shopper methodology to assess YMSM’s testing experiences in three metropolitan cities highly impacted by the HIV epidemic.
HIV antiretroviral (ART) meds cannot completely eradicate the virus; it persists in immune cell “reservoirs.” Now scientists have discovered evidence that the initial use of ART alters the host environment to allow the formation or stabilization of most of the long-lived HIV reservoir.
After a rigorous vetting process, Johns Hopkins University officials announced today their selection of Vines Architecture to lead the planning stages, known as a feasibility study, for a multidisciplinary building that will honor the legacy of Henrietta Lacks.
As part of a massive national effort to improve and modernize flu shots, the Duke Human Vaccine Institute has received three research contracts from the National Institute of Allergy and Infectious Diseases (NIAID), with an initial award of approximately $29.6 million in first-year funding.
Wistar was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to fund an international multidisciplinary clinical research consortium spearheaded by Wistar’s HIV Research Program.
Spending bills released by Senate Appropriations Committee Wednesday demonstrate encouraging recognition of some of the most urgent health challenges threatening individual and public health at home and abroad. At the same time, the bills fall short of the comprehensive commitments necessary to fully effective responses.
The Senate Labor, Health and Human Services and Related Programs Appropriations subcommittee’s allocations of funding for the Ending the HIV Epidemic initiative in its proposed budget for 2020 represent a significant step toward an ambitious, critical, and achievable goal; however, lack of new resources to confront increasing rates of hepatitis C and sexually transmitted diseases with insufficient support for addressing opioid-related infectious diseases, falls far short of the response to these concurrent epidemics that is needed.
Disparities in rates of sexually transmitted infections (STIs) and HIV between Black/African American and Hispanic/Latino adolescents and their white counterparts are well documented. Culturally and developmentally appropriate efforts targeted to help these youth establish healthy practices to lower their risk of sexually transmitted infections are warranted. However, such interventions present unique challenges in recruiting and retaining research participants.
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease. A report on the findings was published in August in EClinicalMedicine.
Tuberculosis and HIV – two of the world’s deadliest infectious diseases – are far worse when they occur together. Now, Texas Biomedical Research Institute researchers have pinpointed an important mechanism at work in this troubling health problem. And, their discovery could lead to a new mode of treatment for people at risk.